Reviewing Zenas Biopharma (ZBIO) & Its Peers

Zenas Biopharma (NASDAQ:ZBIO) is one of 422 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Zenas Biopharma to similar businesses based on the strength of its risk, profitability, institutional ownership, analyst recommendations, earnings, dividends and valuation.

Earnings & Valuation

This table compares Zenas Biopharma and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zenas Biopharma	$5.00 million	N/A	-2.30
Zenas Biopharma Competitors	$154.14 million	-$11.26 million	-55.54

Zenas Biopharma’s competitors have higher revenue, but lower earnings than Zenas Biopharma. Zenas Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Dividends

Zenas Biopharma pays an annual dividend of $0.05 per share and has a dividend yield of 0.6%. Zenas Biopharma pays out -1.4% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 4.1% and pay out 116.1% of their earnings in the form of a dividend.

Institutional and Insider Ownership

29.3% of shares of all “Biotechnology” companies are owned by institutional investors. 22.5% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Zenas Biopharma and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas Biopharma	0	0	2	0	3.00
Zenas Biopharma Competitors	825	2263	4730	56	2.51

Zenas Biopharma presently has a consensus price target of $40.00, suggesting a potential upside of 389.60%. As a group, “Biotechnology” companies have a potential upside of 47.36%. Given Zenas Biopharma’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Zenas Biopharma is more favorable than its competitors.

Profitability

This table compares Zenas Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas Biopharma	N/A	N/A	N/A
Zenas Biopharma Competitors	-14,682.20%	39.10%	-32.41%

Summary

Zenas Biopharma beats its competitors on 7 of the 13 factors compared.

Zenas Biopharma Company Profile

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.